News & Views
Prosensa Wins Emerging Star Award
Jun 28 2012
Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, won the Emerging Star accolade at the European Mediscience Awards (London, June 21).
Supported by Peel Hunt, the inaugural Emerging Star Award celebrates the achievements of a private or young public mediscience company that has demonstrable credibility in terms of business model/strategy, management team and financing. The winner's focus on innovation is also key, with its technology/IP capable of significant market impact or disruption.
Collecting the award, Dr.Giles Campion, Prosensa’s Chief Medical Officer and SVP Research & Development said: “We are very pleased to be recognised by the European Mediscience judging panel. This prestigious award is an additional motivation in our efforts to help patients and their families affected by rare, progressively debilitating diseases.”
Prosensa has the most advanced portfolio of drug candidates for the treatment of Duchenne muscular dystrophy (DMD), with two compounds in clinical trials in partnership with GlaxoSmithKline and four additional compounds in late stage pre-clinical development.
Prosensa’s DMD compounds are based on its proprietary exon-skipping technology that uses antisense oligonucleotides to restore expression of a functional dystrophin protein and to provide potential treatment for patients affected by this progressively debilitating neuromuscular disease.
The company recently raised €23 million in a private equity financing round and is supported by a consortium of investors including Abingworth, Gimv, Idinvest Partners, Life Sciences Partners, MedSciences Capital and New Enterprise Associates.
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan